Press release
Epilepsy Pipeline: Clinical Trials, Growth Prospects, Insights into Novel and Emerging Pipeline Therapies, Key Companies, and Treatment Landscape | DelveInsight
Epilepsy Pipeline
To know more in detail about Epilepsy Pipeline report, click here: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the essential takeaways from the Epilepsy Pipeline report:
• DelveInsight's Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.
• Major pharmaceutical companies are developing potential drug candidates to improve the Epilepsy treatment scenario, such as Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
• Key Epilepsy pipeline therapies such as OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others are under investigation in different phases of clinical trials.
• In January 2021, Addex Therapeutics announced that its partner Janssen Pharmaceuticals had received FDA's Investigational New Drug (IND) approval to begin a Phase IIa proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with Epilepsy.
• In October 2020, PTC Therapeutics announced the initiation of a registration-directed Phase II/III clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial Epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.
Request for Epilepsy sample report to learn more about trends in specific geographies @ Epilepsy Emerging Therapies and Forecast: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Epilepsy pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Epilepsy products, comprehensive assessment of driving and restraining factors, and opportunities as well as risks in the Epilepsy pipeline landscape.
Epilepsy Overview
Epilepsy is a chronic neurological disorder characterized by frequent and recurring seizures leading to unusual behaviour. The primary cause of Epilepsy is not clear, but it is noted that any change in the nerve cells, neurons, and the brain resulting in abnormal signals can be the possible reason.
The most common symptom of Epilepsy includes seizures; however, additional symptoms like convulsion without fever, low consciousness, less awareness, loss of taste, smell, sight, hearing, etc., can also be present.
For further information about Epilepsy treatment and pipeline therapies, visit @ Epilepsy Pipeline Assessment: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Epilepsy Pipeline Drugs
• OPC-214870: Otsuka Pharmaceutical Co. Ltd
• CT-010: Cerebral Therapeutics LLC
• Ganaxolone: Marinus Pharmaceuticals
• XEN496: Xenon Pharmaceuticals
• Vatiquinone: PTC Therapeutics
• E-2730: Eisai
• NBI 827104: Neurocrine Biosciences
Request for Sample to know more @ Epilepsy Pipeline Analysis and Trends: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Epilepsy Therapeutics Assessment
The Epilepsy Pipeline report proffers an integral view of the Epilepsy emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
• Mono
• Combination
• Mono/Combination
By Stage
• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
By Route of Administration
• Subcutaneous
• Intravenous
• Oral
• Intraventricular
• Inhalation
By Molecule Type
• Gene therapy
• Stem cell therapy
• Small molecules
• Pyridines
By Mechanism of Action
• 4-aminobutyrate transaminase inhibitors
• GABA A receptor agonists
• KCNQ potassium channel agonists
• NQO1 modulators
• Serotonin receptor agonists
• T type calcium channel antagonists
By Targets
• GABA A receptor
• KCNQ potassium channel
• Serotonin receptor
• NQO1
• T type calcium channel
• Synaptic transmission
Scope of the Epilepsy Pipeline Report
• Coverage: Global
• Major Players: Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
• Key Epilepsy Pipeline Therapies: OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.
Dive deep into rich insights of Epilepsy novel and emerging drugs and their analysis @ Epilepsy Pipeline Emerging Novel Therapies: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1 Introduction
2 Executive Summary
3 Epilepsy: Overview
4 Epilepsy - Analytical Perspective In-depth Commercial Assessment
5 Pipeline Therapeutics
6 Late Stage Products (Phase III)
7 Late Stage Products (Phase II/III)
8 Mid Stage Products (Phase II)
9 Early Stage Products (Phase I)
10 Therapeutic Assessment
11 Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Epilepsy Key Companies
14 Epilepsy Key Products
15 Epilepsy- Unmet Needs
16 Epilepsy- Market Drivers and Barriers
17 Epilepsy- Future Perspectives and Conclusion
18 Epilepsy Analyst Views
19 Appendix
20 About DelveInsight
Get Epilepsy customized report @ Epilepsy Emerging Therapies: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epilepsy Pipeline: Clinical Trials, Growth Prospects, Insights into Novel and Emerging Pipeline Therapies, Key Companies, and Treatment Landscape | DelveInsight here
News-ID: 2803304 • Views: …
More Releases from DelveInsight Business Research
Global Patient Engagement Solutions Market to reach USD 59,499.28 million by 203 …
According to DelveInsight's analysis, The growth of the patient engagement solutions market is primarily fueled by several major factors, including the increasing burden of chronic conditions such as diabetes and cardiovascular diseases, which require continuous patient involvement and monitoring. The industry is further propelled by the move toward patient-centric healthcare models, ongoing technological innovations, and the introduction of new digital tools and platforms. Moreover, supportive government policies and initiatives aimed…
Global Magnetic Resonance Imaging Devices Market to reach USD 13,553.33 million …
According to DelveInsight's analysis, The growing incidence of chronic illnesses-including heart disease, cancer, and neurological disorders is driving demand for advanced diagnostic methods such as MRI, which provides highly detailed imaging of soft tissues and internal organs. Increasing awareness and a stronger focus on early disease detection are also prompting both patients and healthcare professionals to rely on MRI for faster and more accurate diagnosis. In addition, ongoing technological progress…
Global Microbial Fermentation Technology Market Size was USD 33,956.10 million i …
According to DelveInsight's analysis, The microbial fermentation technology market is experiencing strong growth, largely due to the increasing incidence of chronic illnesses such as cancer and a range of infectious diseases, including HIV, hepatitis B and C, and influenza. The market is also being boosted by the rising need for advanced therapeutic products like cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies. Moreover, progress in synthetic biology and precision…
Global Surgical Robotic System Market to reach USD 29,785.13 million by 2032 at …
According to DelveInsight's analysis, The growing prevalence of chronic illnesses such as cancer, cardiovascular diseases, and orthopedic disorders is driving demand for advanced surgical solutions, which in turn is accelerating the expansion of the surgical robotic systems market. Since many of these conditions require complex, highly precise procedures, robotic-assisted surgery is becoming a preferred option due to its superior precision, less invasive nature, and faster patient recovery. At the same…
More Releases for Epilepsy
Adult mitochondrial epilepsy presentation
Mitochondrial epilepsy is a rare but severe neurological condition caused by genetic mutations that impair mitochondrial function, disrupting cellular energy production in the brain. Patients often present with seizures, developmental delays, and neurodegeneration. It is closely associated with broader mitochondrial diseases such as MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) and Leigh syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72869
Due to its rarity and complexity, treatment options…
Portable Epilepsy Monitoring Market in 2025
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Portable Epilepsy Monitoring Market- (By Product Type (Device Type (Chest Sensor, Watch Sensor, Monitors, Cameras, Mattresses and Pillows, and Others) and Service), By End User (Hospitals, Ambulatory Surgery Centres & Clinics, Neurology Centres, and Home Care Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global…
Top 10 Epilepsy Companies Analysis (2024)
Epilepsy also known as seizure disorder, is a chronic noncommunicable disease that affects brain. Epilepsy affects people of all races, ethnic backgrounds, genders, and ages.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00016405/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Epilepsy Market are:
• Idexx Laboratories Inc.
• PBD Biotech Ltd
• Thermo Fisher Scientific Inc.
• Innovative Diagnostics SAS
• Neogen Corp
• Enfer Labs
• bioMerieux SA
• Ring Biotechnology Co Ltd
• Bionote Inc.
• Shenzhen Bioeasy Biotechnology Co Ltd.
Contact Us:
If you have any queries about this report or if…
Epilepsy Market: Trends, Opportunities, and Challenges
Epilepsy is a neurological disorder characterized by recurrent seizures, which are caused by abnormal electrical activity in the brain. This condition affects millions of people globally, making it one of the most common neurological disorders. As the global burden of epilepsy increases, the demand for effective treatments and solutions continues to grow. The epilepsy market is evolving rapidly, with advancements in medication, diagnostics, and therapeutic technologies. This guest post aims…
Epilepsy Device Market: for Epilepsy Devices Poised to Exceed $1 Billion by 2031 …
The global epilepsy devices market isx experiencing a remarkable surge, poised to exceed a valuation of $1.1 billion by 2031, as revealed by the latest market analysis. According to the report released by Allied Market Research, the market was valued at $675.23 million in 2021 and is projected to grow at a CAGR of 5.1% from 2022 to 2031.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://www.alliedmarketresearch.com/request-sample/A14821
Epilepsy devices play…
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market - Breaking the Sei …
Newark, New Castle, USA: The "Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market: https://www.growthplusreports.com/report/epilepsy-with-myoclonic-atonic-seizures-therapeutics-market/8029
This…
